Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
| Autor: | John, Thomas, Grohé, Christian, Goldman, Jonathan W., Shepherd, Frances A., de Marinis, Filippo, Kato, Terufumi, Wang, Qun, Su, Wu-Chou, Choi, Jin Hyuk, Sriuranpong, Virote, Melotti, Barbara, Fidler, Mary J., Chen, Jun, Albayaty, Muna, Stachowiak, Marta, Taggart, Sarah, Wu, Yi-Long, Tsuboi, Masahiro, Herbst, Roy S., Majem, Margarita |
|---|---|
| Zdroj: | In Journal of Thoracic Oncology September 2023 18(9):1209-1221 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|